Rhythm falls after earnings as amended LG Chem deal and launch details weigh

What happened

Rhythm (RYTM) fell 7.5% on November 3, 2026, because of its third-quarter earnings release and an amended licensing deal with LG Chem that includes $350 million in fixed payments. The company reported third-quarter global net product sales of IMCIVREE of $92.1 million and a quarterly loss of $0.61 per share versus a year-ago loss of $0.82, numbers that beat the Zacks consensus loss estimate of $0.68. Rhythm also said there were more than 700 patient start forms for IMCIVREE as of September 30, 2026, and that the Japan commercial launch for acquired hypothalamic obesity is underway, according to GlobeNewsWire and Seeking Alpha.

How big was the move

The stock fell 7.5% on the day, a decline the data classifies as 3.4 times a typical daily move for this stock. Trading volume was 9.9 times its 20-day average, signaling unusually heavy activity. Rhythm opened 9.2% below the previous close and underperformed the healthcare sector median by 8.1 percentage points on the day; the sector median rose 0.6% while the S&P 500 rose 0.4%.

The session came on a market capitalization of $6.37 billion and with the stock’s beta at 1.47, meaning it tends to move more than the market. In the past five years the stock had 36 sessions with a decline of at least 7.5%; twenty trading days later the median result was a gain of 7.0% and 22 of 36 were higher, which suggests similar sell-offs have often recovered.

The technical picture

Technically, the stock was 3.6% below its 20-day moving average and 10.3% below its 50-day moving average; the 50-day average is below the 200-day average, a sign of a weak longer-term trend. Rhythm was 10.8% below its 200-day moving average and 29.3% below the 52-week high, with the Relative Strength Index (14 days) at 37, in a neutral range.

Momentum has turned negative over recent months. Over one month the stock fell 6.5% and over three months it fell 21.9%; over one year it fell 24.0% and was 34.7 percentage points behind the S&P 500. Volatility measured 35% annualized over 60 days, which is lower than 97% of its own readings over five years, indicating recent swings have been more muted compared with the stock’s history.

Fundamentals and valuation

For the four quarters through September 30, 2026, Rhythm reported revenue of $280.7 million, which grew 61.0% from a year earlier. Gross margin was 88.2%, down from 89.4% a year earlier, while operating margin was 66.7%, down from 106.8% a year earlier. Diluted earnings per share for the period were $-2.90, free-cash-flow margin was 29.6%, return on invested capital was 63.8% and the balance sheet showed net cash of $36.5 million.

Free-cash-flow yield stood at 1.3% and the share count over one year increased by 7.3%. Those figures point to a company generating healthy margins and cash relative to sales growth, but with a modest yield and a reduced operating margin year over year as Rhythm invests in international expansion and development.

Earnings and analyst expectations

Rhythm’s last report, on November 3, 2026, showed earnings per share of $-0.61 against $-0.71 expected, 14.0% above estimates, marking four consecutive quarters beating estimates and an average surprise over the last four reports of 8.7% above estimates. The typical two-day reaction after recent reports was unchanged. The next report is scheduled for February 25, 2027.

Analysts remain broadly positive: the consensus price target is $144.43, 67.1% above the closing price, based on 22 analysts with ratings. One hundred percent of the ratings are Buy or Strong Buy and the consensus rating is Buy. PromtFinance scores rank Rhythm highly for growth at 97 and for revisions at 93, while momentum sits at 31, reflecting recent share weakness.

What to watch

• November 3, 2026: third-quarter global net product sales of IMCIVREE of $92.1 million and more than 700 patient start forms as of September 30, 2026, reported by GlobeNewsWire and Seeking Alpha
• November 3, 2026: amended exclusive license agreement with LG Chem changing the royalty rate to 1% and additional fixed payments totaling $350 million over four years, reported by GlobeNewsWire
• Company guidance or commentary on the timing and expected cost impact of the LG Chem payments in upcoming investor communications
• Progress updates and timing for Phase III plans for bivamelagon in acquired hypothalamic obesity and Prader-Willi syndrome, and international commercial expansion for IMCIVREE
• February 25, 2027: next earnings report